SCHEMBL421077

SCHEMBL421077

CCCCCC[N]N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1795029 1.00 MEN1 (0.52)
SCHEMBL1797937 0.97
SCHEMBL732356 0.87
SCHEMBL16566360 0.77
SCHEMBL9206028 0.76 TSHR (0.61)
SCHEMBL7697182 0.76 TSHR (0.61)
SCHEMBL4389498 0.76 TSHR (0.61)
SCHEMBL277225 0.76 TSHR (0.61)
SCHEMBL4399689 0.76 TSHR (0.61)
SCHEMBL7699808 0.76 TSHR (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434354-B1 SEPARATION MATERIAL FOR BLOOD COAGULATION FACTOR, PREPARATION AND USE THEREOF KURITA WATER INDUSTRIES LTD. (JP) 1993-08-11 EP claimed
US-5096593-A SEPARATION MATERIAL DERIVED FROM GLUCOMANNAN FOR BLOOD COAGULATION FACTOR, PREPARATION AND USE THEREOF KURITA WATER INDUSTRIES LTD. (JP) 1992-03-17 US claimed
US-20240158421-A1 NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2024-05-16 US disclosed
US-11691995-B2 Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-07-04 US disclosed
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2022-01-27 US disclosed
EP-3882239-A1 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2021-09-22 EP disclosed
CN-113302184-A 1,3, 4-oxadiazolinone compounds and drugs 日本新药株式会社 2021-08-24 CN disclosed
CN-107454900-B Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer 蒙彼利埃大学 2020-08-07 CN disclosed
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
EP-3556401-A1 NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS The University of North Carolina at Chapel Hill (US) 2019-10-23 EP disclosed
EP-2669269-B1 NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS UNIV NORTH CAROLINA CHAPEL HILL (US) 2019-05-22 EP disclosed
US-6495542-B1 SUCH AS 2-METHOXY-N-(2-METHYL-1H-BENZIMIDAZOL-4-YL)-4-(2,3,4,5-TETRAHYDRO-5-OXO-1H-1-BENZAZEPIN-1-YL)CARBONYL-BENZAM IDE; HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
EP-1051415-A1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-11-15 EP disclosed
WO-1999037637-A1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-07-29 WO disclosed
US-5646154-A Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 1997-07-08 US disclosed
EP-0664128-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING TUMOR NECROSIS FACTOR PRODUCTION SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1995-07-26 EP disclosed
EP-0434354-B1 SEPARATION MATERIAL FOR BLOOD COAGULATION FACTOR, PREPARATION AND USE THEREOF KURITA WATER INDUSTRIES LTD. (JP) 1993-08-11 EP disclosed
US-5096593-A SEPARATION MATERIAL DERIVED FROM GLUCOMANNAN FOR BLOOD COAGULATION FACTOR, PREPARATION AND USE THEREOF KURITA WATER INDUSTRIES LTD. (JP) 1992-03-17 US disclosed
EP-0434354-A1 Separation material for blood coagulation factor, preparation and use thereof KURITA WATER INDUSTRIES LTD. (JP) 1991-06-26 EP disclosed
EP-0407816-A2 Base modified nucleosides ABBOTT LABORATORIES (US) 1991-01-16 EP disclosed